- COPD is diagnosed with symptoms plus spirometry, and the main long-term treatments are inhalers, stopping smoking, pulmonary rehabilitation and, for some people, oxygen. The GOLD strategy report describes itself as an "evidence-based strategy document" (GOLD 2025 report page). A newer GOLD 2026 edition has since been published, so check the current report. We could not open the NICE NG115 recommendations in this pass (NICE NG115).
- Long-term oxygen for COPD with moderate desaturation did not reduce death or hospital admission. The composite hazard ratio was 0.94 (95% CI 0.79 to 1.12) across 738 patients (LOTT, NEJM 2016). The trial was funded by the US National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services.
- A one-year placebo-controlled trial of daily azithromycin 250 mg cut the rate of exacerbations (hazard ratio 0.73, 95% CI 0.63 to 0.84). Hearing decrements were more common on azithromycin (25% vs 20%, P=0.04, a difference the authors disputed), and macrolide resistance was higher among people who became colonised (81% vs 41%) (MACRO, Albert et al., NEJM 2011). Its funding statement names the US National Institutes of Health.
- Triple inhaler trials report fewer exacerbations than dual inhalers, but they add a corticosteroid, and pneumonia is the consistent safety signal. In IMPACT, the exacerbation rate was 0.91 a year on triple therapy vs 1.21 on the dual therapy (IMPACT, Lipson et al., NEJM 2018). The ETHOS trial in 8,509 people is in the same family (ETHOS, Rabe et al., NEJM 2020).
- Money trail: IMPACT is "Funded by GlaxoSmithKline" (the sponsor's own product, a GSK single inhaler), so we grade it self-interested, tier 4. ETHOS is funded by AstraZeneca, also tier 4. The two largest triple-therapy trials are therefore both sponsor-funded. The two public trials in this article, LOTT and MACRO, were funded by US government bodies. We did not verify market data or documented integrity events for the inhaler makers in this pass.
- The 2016 Cochrane review of intravenous alpha-1 antitrypsin for alpha-1 deficiency found the trials too small and too short to show that the treatment reduces death or lung function decline. It notes that the largest trial's authors had "numerous financial conflicts of interest" (Gøtzsche & Johansen, Cochrane 2016).
- Evidence grade: Moderate that long-term oxygen is not beneficial for moderate desaturation (one large public-funded trial). Moderate that daily azithromycin reduces exacerbations, with a hearing and resistance trade-off. Weak to Insufficient for supplements and alpha-1 augmentation. Risk for pneumonia with inhaled corticosteroids.
Independent evidence review · Lung condition
The best independent evidence says that COPD treatment is built on inhalers, stopping smoking and rehabilitation, with long-term oxygen not helping people whose oxygen levels are only moderately low. Triple inhalers reduce flare-ups in the trials, but the largest triple-therapy trials were paid for by the companies that sell them, and inhaled corticosteroids carry a consistent pneumonia risk. Our confidence is moderate for the oxygen and azithromycin findings and low for the long-term benefit of triple therapy beyond the sponsor-funded trials. This is a partial review. Several primary sources were blocked to our tools, and we say so each time.
Table of contents
- Evidence summary
- What COPD is and how it is diagnosed
- How the main treatments work
- What works and what does not
- Benefits by claim
- Risks and side effects
- Interactions and cautions
- Who needs extra care
- Doses studied and treatment forms
- Follow the money: who makes it and who funded the evidence
- Related research
- Frequently asked questions
- Sources and funding notes
Evidence summary
| Claim | Evidence | Source | Funding / conflict | Strength |
|---|---|---|---|---|
| Long-term oxygen helps people with COPD and moderate desaturation | 738 patients; composite of death or first hospital admission HR 0.94 (95% CI 0.79 to 1.12) | LOTT, NEJM 2016 | Funded by NHLBI and CMS (US government). Author disclosure forms not checked in this pass. | Moderate (no benefit shown) |
| Daily azithromycin reduces exacerbations | One-year placebo-controlled RCT; exacerbation HR 0.73 (95% CI 0.63 to 0.84) | MACRO, NEJM 2011 | Funding statement names the US National Institutes of Health | Moderate |
| Azithromycin harms | Hearing decrements in 25% vs 20% of people (P=0.04; the authors disputed the test's strictness); macrolide resistance 81% vs 41% among people who became colonised | MACRO, NEJM 2011 | As above | Risk |
| Triple inhaler reduces moderate to severe exacerbations vs dual inhaler | 10,355 patients, 52 weeks; annual rate 0.91 (triple) vs 1.21 (dual LAMA+LABA) | IMPACT, NEJM 2018 | "Funded by GlaxoSmithKline" (tier 4). A secondary journal-club summary reports that the lead author is a sponsor employee; the paper's disclosure forms were not checked. | Weak to moderate (sponsor-funded) |
| Triple inhaler reduces exacerbations (second pivotal trial) | 8,509 patients; budesonide-based triple therapy vs glycopyrronium-formoterol | ETHOS, NEJM 2020 | Funded by AstraZeneca (tier 4). Author disclosure forms not checked in this pass. | Weak to moderate (sponsor-funded) |
| Inhaled corticosteroids increase pneumonia | Pneumonia more common in arms that include an inhaled corticosteroid (IMPACT). Cochrane 2023 (CD012066): LABA+ICS vs LAMA+LABA, pneumonia 5% vs 3% (OR 0.61, high certainty) | IMPACT; Cochrane 2023 (CD012066) | Cochrane funding not stated in the abstract we could read | Risk |
| Pulmonary rehabilitation helps symptoms and daily function | Cochrane review, updated 2015; we could read the record but not the full conclusions | McCarthy et al., Cochrane 2015 | No funding sentence in the abstract; author ties to included trials not checked | Moderate (conclusion not checked in full) |
| IV alpha-1 antitrypsin slows lung damage in alpha-1 deficiency | Few small trials; mortality and harms poorly reported | Gøtzsche & Johansen, Cochrane 2016 | No funding stated; authors of the largest trial had "numerous financial conflicts of interest" | Insufficient |
Independent evidence and credibility scorecard
Tier legend: Tier 1 independent (public or non-commercial funding, no known stake in the result). Tier 2 indirect ties (public funding but author or sponsor ties, or funding not stated). Tier 3 interested party (trade body, advocacy group). Tier 4 self-interested (funded or run by the maker). Credibility: A high, B solid with bias to watch, C interested, D self-interested.
| Source | Who funds it | Country | Independence tier (1–4) | Credibility (A–D) | Why it would tell the truth / residual bias |
|---|---|---|---|---|---|
| LOTT trial, NEJM 2016 | NHLBI and CMS (US government) | USA | 2 | B | Public funding with a negative result, which is a reason to trust it. Residual bias: author disclosure forms were not checked in this pass. |
| MACRO trial, NEJM 2011 | US National Institutes of Health | USA | 1 | B | Public funding and a placebo control. Residual bias: a single trial, and a positive result from an academic network that rewards novel findings. |
| Cochrane pulmonary rehabilitation review, 2015 | Not stated in abstract (Cochrane reviews are funded by Cochrane's own sources and grants; not verified here) | International (Cochrane; base not verified) | 2 | B | Systematic review with a reputation to protect. Residual bias: author ties to included trials were not checked in this pass. |
| Cochrane LAMA+LABA vs LABA+ICS review, 2023 (CD012066) | Not stated in abstract | International (Cochrane; base not verified) | 2 | B | Systematic review. Pneumonia 5% vs 3% (OR 0.61, high certainty); all-cause death 1% vs 1.4% (OR 1.35, moderate certainty, very few events). Residual bias: the sponsors of its included trials were not checked in this pass. |
| Cochrane alpha-1 antitrypsin review, 2016 | No funding stated | Denmark (lead author; not checked against the review record) | 2 | B | Systematic review that flags conflicts in the largest trial. Residual bias: the funding of the three included trials was not checked in this pass. |
| GOLD 2025 report | Not stated on the page we opened; sells reports and bulk orders | Not verified | 2 | C | Its reputation depends on clinicians trusting it, but its funding and conflict policy were not visible on the page. Full report not reviewed. |
| IMPACT trial, NEJM 2018 | GlaxoSmithKline ("Funded by GlaxoSmithKline") | UK (GSK plc) | 4 | D | Peer-reviewed in a leading journal, but the sponsor makes the product tested. Residual bias: sponsor-run design and a commercial interest in the outcome. |
| ETHOS trial, NEJM 2020 | AstraZeneca ("Funded by AstraZeneca") | UK (AstraZeneca plc) | 4 | D | Peer-reviewed, but the sponsor makes the product tested. Residual bias: a commercial interest in the outcome, and an author group with multiple industry ties. |
Convergence: the two sponsor-funded triple-therapy trials agree in direction, with fewer exacerbations than dual therapy. The independent sources agree that pneumonia is a concern with inhaled corticosteroids. The 2023 Cochrane review shows fewer pneumonias on LAMA plus LABA than on LABA plus ICS, but also a small rise in all-cause death (odds ratio 1.35, very few events). Most sources cluster in the United States and the United Kingdom, so the verdict reflects those health systems.
What COPD is and how it is diagnosed
COPD is a long-term lung disease that makes breathing out difficult. Diagnosis depends on symptoms such as breathlessness, cough and sputum, together with spirometry, which measures how much air a person can blow out. The GOLD report describes its 2025 edition as an evidence-based strategy document for diagnosis, management and prevention (GOLD 2025 report page). A GOLD 2026 edition has since been published, so check the current report. We could not open the spirometry thresholds in the full report or the NICE NG115 recommendations (NICE NG115), so this article does not restate them.
How the main treatments work
Inhaled bronchodilators relax the airway muscles. Inhaled corticosteroids reduce airway inflammation, and that is why they are combined with bronchodilators in triple inhalers. Oxygen treats low blood oxygen levels. Azithromycin is an antibiotic that is used for its anti-inflammatory effect in long-term prevention. Each mechanism is supported more by trial outcomes than by a proven mechanism in people, so we report outcomes rather than biology.
What works and what does not
| Treatment | Evidence in this review | Result |
|---|---|---|
| Long-term oxygen for moderate desaturation | LOTT, 738 patients (NEJM 2016) | No benefit shown |
| Daily azithromycin for exacerbations | MACRO, 1,142 patients (NEJM 2011) | Fewer exacerbations |
| Triple inhaler vs dual inhaler | IMPACT and ETHOS (sponsor-funded) | Fewer exacerbations; pneumonia risk |
| Pulmonary rehabilitation | Cochrane 2015 (record) | Conclusion not checked in full |
| IV alpha-1 antitrypsin for alpha-1 deficiency | Cochrane 2016 (record) | Insufficient evidence |
| Supplements (for example antioxidants or vitamins) | Not reviewed in this pass | Not graded |
Benefits by claim
Does long-term oxygen help people with COPD?
In LOTT, people with COPD and moderate desaturation who received long-term oxygen did not have fewer deaths or hospital admissions than people who did not. The composite hazard ratio was 0.94 (95% CI 0.79 to 1.12; P=0.52) (LOTT, NEJM 2016). Its finding should be read as applying to the moderate-desaturation group it studied.
Does daily azithromycin prevent flare-ups?
In MACRO, daily azithromycin 250 mg reduced the rate of exacerbations (hazard ratio 0.73, 95% CI 0.63 to 0.84). The median time to a first exacerbation was 266 days on azithromycin and 174 days on placebo (MACRO, NEJM 2011). This is an academic trial funded by the US National Institutes of Health.
Do triple inhalers prevent flare-ups?
In IMPACT, annual rates of moderate to severe exacerbations were 0.91 on triple therapy, 1.07 on fluticasone furoate with vilanterol and 1.21 on umeclidinium with vilanterol, over 52 weeks and 10,355 patients (IMPACT, NEJM 2018). ETHOS reported fewer moderate or severe exacerbations on budesonide-based triple therapy than on glycopyrronium with formoterol (ETHOS, NEJM 2020). Both trials are sponsor-funded, so the benefit should be read as the sponsor's result until independent trials confirm it.
Does pulmonary rehabilitation help?
A Cochrane review first published in 1996 and most recently updated in 2015 covers pulmonary rehabilitation for COPD (McCarthy et al., Cochrane 2015). We could read its record but not the effect sizes, so we do not quote a number here. The review's abstract does not state a funder.
Does alpha-1 antitrypsin treatment slow lung damage?
The 2016 Cochrane review found few trials, small numbers, and poor reporting of deaths and harms, so it could not show a benefit on death or lung function (Gøtzsche & Johansen, Cochrane 2016). The review's abstract notes that the largest trial's authors had "numerous financial conflicts of interest".
Risks and side effects
Interactions and cautions
We did not review a full interaction database in this pass. Any interaction question about an inhaler, azithromycin or oxygen should go to a pharmacist, who can check the individual medicines list. Azithromycin can affect heart rhythm in some people, so a clinician should review it alongside other medicines that affect the heart.
Who needs extra care
The MACRO trial excluded people with hearing impairment, resting tachycardia or a meaningful risk of QT prolongation (MACRO, NEJM 2011). Anyone with those features needs specialist advice before azithromycin is considered. People with a history of pneumonia have a particular reason to weigh the corticosteroid risk in triple inhalers.
Doses studied and treatment forms
Doses studied: azithromycin 250 mg once daily for one year (MACRO). Long-term oxygen was studied in people with moderate desaturation (LOTT). Triple inhalers were studied once daily (IMPACT, a single inhaler) and twice daily (ETHOS, budesonide-based). These are trial doses, not advice. Product quality and inhaler technique are a clinician or pharmacist question.
Follow the money: who makes it and who funded the evidence
Who makes and sells the inhalers
The IMPACT triple inhaler is Trelegy Ellipta, marketed by GlaxoSmithKline. Innoviva's 2021 SEC filing says it receives 15% of the royalty payments GSK makes to Theravance Respiratory Company on Trelegy; Trelegy net sales were $445.6 million in Q3 2021. The ETHOS trial tested budesonide, glycopyrronium and formoterol, and it was funded by AstraZeneca. Current sales and royalty shares were not checked beyond these 2021 filings.
Who funded the evidence
The two largest triple-therapy trials were sponsor-funded. IMPACT states "Funded by GlaxoSmithKline" (NEJM 2018), and ETHOS states it was funded by AstraZeneca (NEJM 2020; funding wording from a search-result summary of the abstract, full text blocked). The public trials, LOTT and MACRO, were funded by US government bodies.
Integrity events
We did not find or verify documented regulatory warning letters, recalls or lawsuits for the COPD inhaler makers in this pass. That is a gap, not evidence that none exist.
Research funding at a glance
8 sources graded. The counts below are the independence tiers assigned in the scorecard above. They count sources, not funding amounts or evidence quality.
Public funding alone does not prove independence, and commercial funding alone does not prove a claim false. Named funders, countries and relationships are in the scorecard and source notes.
Related research
- Asthma Prevention and Management: Evidence and Safety Guide
- Asthma Supplements: Nutritional Roles, Evidence Limits and Safety
- Smoking and Heart Disease: Quitting Support, Vaping and Medicine Safety
- Bupropion: Independent Evidence on Depression, Quitting Smoking & Side Effects
- Pulmonary Hypertension: Types, Diagnosis, Treatment and Evidence Funding
- Non-small cell lung cancer (NSCLC): symptoms, tests, stages and care
Frequently asked questions
Does long-term oxygen help everyone with COPD?
No. In the LOTT trial, long-term oxygen did not reduce death or hospital admission in people with moderate desaturation (HR 0.94, 95% CI 0.79 to 1.12; NEJM 2016). The trial does not cover people with much lower oxygen levels.
Is azithromycin a treatment for COPD?
In the MACRO trial, daily azithromycin 250 mg reduced exacerbations over one year (HR 0.73, 95% CI 0.63 to 0.84), but hearing decrements were more common (25% vs 20%) and resistant bacteria increased (NEJM 2011). Decisions belong with a specialist.
Do triple inhalers work better than two-drug inhalers?
The IMPACT and ETHOS trials report fewer exacerbations on triple therapy (IMPACT; ETHOS). Both were sponsor-funded, so their results need independent replication.
Are triple inhalers linked to pneumonia?
Pneumonia was more common in arms that included an inhaled corticosteroid in the IMPACT trial (NEJM 2018). A 2023 Cochrane review (CD012066) reports pneumonia in 5% of people on LABA plus ICS vs 3% on LAMA plus LABA (odds ratio 0.61, high certainty).
Who funded the main triple-inhaler trials?
IMPACT states "Funded by GlaxoSmithKline" (NEJM 2018). ETHOS was funded by AstraZeneca (NEJM 2020).
Does pulmonary rehabilitation work?
A Cochrane review covers pulmonary rehabilitation for COPD (McCarthy et al., 2015). We could not read its conclusions in full, so this article does not quote its effect sizes.
Can alpha-1 antitrypsin infusions slow COPD?
The 2016 Cochrane review found too few trials and too little outcome data to show a benefit on death or lung function (Gøtzsche & Johansen).
Sources and funding notes
Could not verify or could not open: NICE NG115 (access blocked to our tool, so its recommendations are not quoted); full-text NEJM pages for IMPACT and ETHOS (blocked; funding wording for ETHOS is from a search-result summary of the abstract); PubMed PMC full text for MACRO (blocked; the funding statement is from Europe PMC metadata); full text of the Cochrane reviews (funding not checked; the 2023 pneumonia and mortality figures come from search summaries of the review). Supplements, roflumilast, smoking-cessation pharmacotherapy and COPD-specific market and integrity events were not reviewed in this pass.
- A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation, NEJM 2016. Role: primary trial. Funder: NHLBI (NIH) and CMS.
- Azithromycin for Prevention of Exacerbations of COPD, NEJM 2011. Role: primary trial. Funder: National Institutes of Health.
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD (IMPACT), NEJM 2018. Role: primary trial. Funder: GlaxoSmithKline ("Funded by GlaxoSmithKline").
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD (ETHOS), NEJM 2020. Role: primary trial. Funder: AstraZeneca.
- Cochrane review, LAMA plus LABA versus LABA plus ICS for COPD (CD012066), 2023. Role: systematic review. Funder: not stated in abstract.
- Cochrane review, pulmonary rehabilitation for COPD (McCarthy et al.), 2015. Role: systematic review. Funder: not stated in abstract.
- Cochrane review, intravenous alpha-1 antitrypsin augmentation (Gøtzsche & Johansen), 2016. Role: systematic review. Funder: none stated.
- GOLD 2025 Report page. Role: guideline publisher. Funder: not stated on the page.
Educational research reviewed 9 October 2026. This article is not medical advice; talk to a qualified clinician or pharmacist before starting, stopping or combining treatments.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.